Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Polycythemia Vera 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Breast Cancer Female 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

durvalumab 1abemaciclib 1Saline Solution 1Ketorolac Tromethamine 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Breast Cancer Female × durvalumab × Clear all
NCT04088032 2020-07-16

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Stony Brook University

Phase EARLY_PHASE1 Withdrawn
BreastOther neoplasm

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡